Sogilen
Sogilen is a brand formulation of Cabergoline, an ergot derivative that acts as a potent and long-acting dopamine receptor agonist with high affinity for D2 receptors. By stimulating these receptors in the pituitary gland, it inhibits prolactin secretion. It also interacts with dopamine receptors in the corpus striatum to treat signs and symptoms of Parkinson's disease.
Dosage by Body Weight
For hyperprolactinemia, the recommended initial dosage is 0.5 mg per week given in one or two doses, which may be increased gradually based on prolactin levels. For Parkinson's disease, the initiation dose is typically 1 mg daily. It should be taken with food to reduce gastrointestinal side effects.
- Body Weight
- Below 5 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not recommended
- Frequency
- N/A
- Tracking Notes
- Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not recommended | N/A | Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age. |
| 5-7 kg | Not recommended | N/A | Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age. |
| 8-10 kg | Not recommended | N/A | Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age. |
| 11-15 kg | Not recommended | N/A | Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age. |
| 16-20 kg | Not recommended | N/A | Safety and efficacy of Cabergoline have not been established in pediatric populations under 16 years of age. |
Formulation
Purpose
Used for the treatment of hyperprolactinemic disorders (including dysfunction like amenorrhea, oligomenorrhea, anovulation, and galactorrhea), the prevention or suppression of physiological postpartum lactation, and as adjunctive therapy in Parkinson's disease.
Generic Name
CabergolineScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.